医学
醛固酮
氯沙坦
内科学
氨氯地平
血压
心脏病学
原发性高血压
内分泌学
泌尿科
血管紧张素II
作者
Chikako Yoshida,Akiko Goda,Yoshiro Naito,Ayumi Nakaboh,Mika Matsumoto,Misato Otsuka,Mitsumasa Ohyanagi,Shinichi Hirotani,Masaaki Lee‐Kawabata,Takeshi Tsujino,Tohru Masuyama
标识
DOI:10.1097/hjh.0b013e32834103d4
摘要
BACKGROUND: Aldosterone is known to bring about damage to various organs; however, it is unclear how important the changes in plasma aldosterone concentration (PAC) are as contributors to regression of left-ventricular (LV) mass in hypertensive patients following long-term treatment with calcium channel blockers (CCBs) or angiotensin II receptor blockers (ARBs). OBJECTIVE: To assess the importance of changes in PAC during antihypertensive treatment. METHODS: Forty-four untreated hypertensive patients were randomly assigned to either CCB (amlodipine) group or ARB (losartan) group. In addition to PAC measurements LV geometry was echocardiographically assessed with LV mass index (LVMI) and relative wall thickness (RWT) before and 6 and 12 months after treatment. RESULTS: Reduction of systolic blood pressure (SBP) in 12 months was greater in the CCB group than in the ARB group (-19 ± 8 vs. -11 ± 15%, P < 0.05 as percentage reduction from the values before treatment). PAC decreased in 12 months in the ARB group but not in the CCB group (-31 ± 31 vs. 17 ± 53%, P < 0.01 as percentage reduction from the values before treatment). Larger percentage drop in PAC was associated with larger percentage reduction of LVMI (r = 0.45, P < 0.01 for all). Multiple step-wise regression analysis showed that the percentage reduction of LVMI is related to the percentage changes in SBP and the percentage changes in PAC (r = 0.46, P < 0.01). CONCLUSION: Regression of LV mass was the larger in patients with the greater decrease in PAC associated with antihypertensive medication regardless of CCB or ARB. Changes in PAC and SBP may be key determinants of regression of LV mass in hypertensive patients regardless of the medication selected.
科研通智能强力驱动
Strongly Powered by AbleSci AI